Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cassava Sciences Inc (NQ: SAVA )

2.750 -0.040 (-1.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cassava Sciences Inc

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Top Biotech Short Squeeze Stocks
Investing in biotechnology stocks offers a unique opportunity for individuals looking to gain exposure to one of the most dynamic and innovative sectors of the market. 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
S&P 500, Nasdaq Hit Record Highs To Start December
Stocks are a mixed bag this afternoon, with the S&P 500 Index and Nasdaq Composite earlier touching fresh record highs as the latter jumps triple digits. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Benzinga Bulls And Bears: Amazon, Tesla, Rivian, Palantir And How Dogecoin Helped Low-Income Families Achieve Homeownership
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Cassava Sciences
Via Benzinga
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today
SAVA, ZM, KSS, RIVN, TSLA were among the trending stocks among investors on Monday Nov. 25, 2024. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
Via Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
Via Benzinga
Topics Economy
Exposures Fossil Fuels Interest Rates
Unpacking the Latest Options Trading Trends in Cassava Sciences
Via Benzinga
How Is The Market Feeling About Cassava Sciences?
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $20,000 Today
Via Benzinga
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its Phase 3 trial. 
Via Benzinga
Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
Cassava Sciences' stock fell after Phase 3 simufilam trial failed to meet key endpoints, prompting the discontinuation of its Alzheimer's studies. 
Via Benzinga
Cassava Sciences Plummets 85% After Embattled Alzheimer's Drug Flops
The company tested simufilam in patients with mild-to-moderate Alzheimer's disease. 
Via Investor's Business Daily
Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Cassava Sciences Unusual Options Activity
Via Benzinga
Friday's Top 5 Trending Stocks: What's The Scoop On GameStop, SoFi, Tesla?
GameStop, SoFi, Tesla, Cassava Sciences and Anavex Life Sciences are the top five trending stocks on Stocktwits Friday. Here's a look at what's going on: 
Via Benzinga
Analysts Believe Cassava Sciences Now Has 300% Upside From Here
Cassava Sciences faces controversy over its Alzheimer's drug, simufilam, amid fraud allegations, yet analysts maintain a Buy rating with high upside potential. 
Via MarketBeat
Topics Fraud Lawsuit
Exposures Criminal Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
Via Benzinga
Exposures Fossil Fuels
What's Going On With Alzheimer's-Focused Cassava Sciences On Tuesday?
Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The firm anticipates top-line results from the ReTHINK Phase 3 trial before... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This Wells Fargo Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Cassava Sciences Stock Dived by Almost 11% Today
Without admitting wrongdoing, the company put a regulatory controversy to rest, but this was expensive. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.